InsiderSignal.AI

InsiderSignal.ai

MIRM - Mirum Pharmaceuticals, Inc.

Insider Purchase by Heron Patrick J (Dir)

3 Months
After Trade
Before Trade

Loading data...

Trade Summary

1 month ago, Heron Patrick J, serving as Dir at Mirum Pharmaceuticals, Inc. (MIRM), purchased 131,425 shares at $68.48 per share, for a total transaction value of $8,999,984.00. Following this transaction, Heron Patrick J now holds 4,031,625 shares of MIRM.

This purchase represents a 3.00% increase in Heron Patrick J's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Friday, January 23, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, January 27, 2026, 4 days after the trade was made.

Mirum Pharmaceuticals, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Heron Patrick J

Dir

Patrick J. Heron is a seasoned life sciences investor and Managing General Partner at Frazier Life Sciences since 1999, where he has led or co-led investments in over 30 companies, including successful exits like ARMO (acquired by Eli Lilly), Ignyta (acquired by Roche), and Silvergate Pharmaceuticals (acquired by CutisPharma).[[1]](https://fintool.com/app/research/companies/ARQT/people/patrick-j-heron)[[3]](https://www.arcutis.com/leadership/patrick-heron/) Prior to Frazier, he developed McKinsey & Company's West Coast biotechnology consulting practice, focusing on mergers, acquisitions, product launches, and research prioritization; he holds a B.A. in Political Science from the University of North Carolina at Chapel Hill (Phi Beta Kappa, Morehead Scholar) and an M.B.A. from Harvard Business School.[[1]](https://fintool.com/app/research/companies/ARQT/people/patrick-j-heron)[[3]](https://www.arcutis.com/leadership/patrick-heron/) Heron serves as a director at MBX Biosciences, Inc. (MBX), where he is designated as Director, 10% Owner, holding approximately 5,219,440 shares, and recently purchased $10 million in IPO shares.[[2]](https://app.boardroomalpha.com/profiles/people/A1065721-PATRICK_J_HERON)[[5]](https://mbxbio.com/about-us/)[[6]](https://www.gurufocus.com/insider/37604/patrick-j-heron)[[7]](https://www.investing.com/news/stock-market-news/mbx-biosciences-director-buys-10-million-in-ipo-shares-93CH-3620488) He is also a Class III independent director and Compensation Committee member at Arcutis Biotherapeutics (ARQT) since 2016, having chaired the board from 2019 to November 2024, and holds directorships at Mirum Pharmaceuticals, HilleVax, and Scout Bio, among others.[[1]](https://fintool.com/app/research/companies/ARQT/people/patrick-j-heron)[[2]](https://app.boardroomalpha.com/profiles/people/A1065721-PATRICK_J_HERON)[[3]](https://www.arcutis.com/leadership/patrick-heron/)

View full insider profile →

Trade Price

$68.48

Quantity

131,425

Total Value

$8,999,984.00

Shares Owned

4,031,625

Trade Date

Friday, January 23, 2026

30 days ago

SEC Filing Date

Tuesday, January 27, 2026

Filed 4 days after trade

HEALTHCAREBIOTECHNOLOGY

About Mirum Pharmaceuticals, Inc.

Company Overview

No company information available
View news mentioning MIRM

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/3474905

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime